Over the years, the treatment landscape of B-cell acute lymphoblastic leukemia (B-ALL) has transformed with the implementation of novel immunotherapies, including CAR-T cells, antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs). Furthermore, chemotherapy-free regimens are being increasingly explored, with several ongoing trials evaluating these.

In this podcast, experts Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Ryan Cassaday, MD, University of Washington, Seattle, WA, share some insights into the growing role of immunotherapy in ALL. Topics covered include the value of novel agents, targeting CD7 in T-ALL, and the possibility of moving away from stem cell transplantation (SCT).

The post The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation appeared first on VJHemOnc.

If J.D. Vance Becomes VP, Should Ukraine & Taiwan Worry?